论文部分内容阅读
目的分析坦索罗辛在晚期前列腺癌中应用的安全性。方法 52例晚期前列腺癌患者,随机分为观察组与对照组,每组26例。两组患者均最大限度的给予雄激素阻断方式治疗,在此基础上,观察组患者加用坦索罗辛治疗,对比观察两组患者的临床治疗效果及治疗安全性。结果治疗后观察组患者最大尿流率、前列腺体积以及剩余尿量等方面均优于对照组(P<0.05);两组患者的血压水平变化及不良反应发生率比较,差异无统计学意义(P>0.05)。结论坦索罗辛在晚期前列腺癌中具有较高的临床疗效及安全性,值得在临床上推广。
Objective To analyze the safety of tamsulosin in advanced prostate cancer. Methods 52 patients with advanced prostate cancer were randomly divided into observation group and control group, with 26 cases in each group. Two groups of patients were given the maximum androgen blockade treatment, on this basis, the observation group plus tamsulosin treatment compared the two groups of patients with clinical treatment and treatment safety. Results After treatment, the maximum urinary flow rate, prostate volume and residual urine volume in observation group were better than those in control group (P <0.05). There was no significant difference in blood pressure level and incidence of adverse reactions between two groups P> 0.05). Conclusion Tamsulosin in advanced prostate cancer has a high clinical efficacy and safety, it is worth clinical promotion.